[Autosomal recessive cerebellar ataxias]

Area of Science:

• Neurogenetics
• Molecular Neurology
• Rare Diseases

Context:

• Autosomal recessive cerebellar ataxias (ARCA) represent a heterogeneous group of inherited neurodegenerative disorders.
• These conditions affect the cerebellum, spinocerebellar tracts, spinal cord posterior columns, and peripheral nerves, often causing significant disability before age 30.
• Friedreich's ataxia (FRDA) is the most common ARCA, with other rarer forms including ataxia with oculomotor apraxia (AOA1, AOA2), ataxia with vitamin E deficiency (AVED), and autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS).

Purpose:

• To review the genetic heterogeneity and common pathogenic pathways involved in various ARCA subtypes.
• To highlight the diagnostic challenges and the need for increased clinical awareness of ARCA.
• To discuss future directions in ARCA research, including novel identification methods and therapeutic development.

Summary:

• ARCA are classified based on affected neurological systems and underlying molecular defects, involving pathways like DNA repair, RNA processing, mitochondrial function, lipoprotein assembly, protein folding, and peroxisomal function.
• Despite their rarity, understanding shared molecular mechanisms is crucial for advancing research.
• Current treatments are available for specific ARCA types, such as FRDA, AVED, abetalipoproteinemia (ABL), and Refsum disease (RD).

Impact:

• Advancements in nanotechnology, high-throughput gene analysis, and bioinformatics are expected to accelerate the discovery of novel ARCA entities.
• The primary challenge remains the development of effective treatments to combat the progressive disability associated with these neurodegenerative disorders.
• Increased clinical awareness of ARCA, particularly FRDA and treatable forms, is essential for timely diagnosis and management.